Masculinising Hormone Therapy Affects Cardiometabolic Risk Factors and Impairs Myocardial Tolerance to Ischaemia/Reperfusion Injury in Mice

Masculinising hormone therapy (MHT) increases cardiovascular disease risk in female-to-male gender transition (FM-GT), but its impact on post-ischaemic cardiac outcomes remains unclear. This study aimed to investigate the effects of different MHT dosages on cardiometabolic risk and myocardial tolerance to ischaemia/reperfusion injury (IRI) in mice.